Industry News

Obamacare Changes Leave Insurers Unmoved [The Hartford Courant]
UnitedHealth Group, are taking immediate action to help people affected by Hurricane Madeline and Hurricane Lester, which are expected to hit Hawaii over the next few days. This includes a free emotional-support line to help people in the..."/>
UnitedHealthcare and Optum Act to Support People Affected by Hurricanes Madeline and Lester
Mallinckrodt, a U.K.-based specialty pharmaceutical company. The acquisition was completed Wednesday; terms were not disclosed. But Madison-based Stratatech will continue operating in Madison and will keep all of its jobs, CEO and founder Lynn Allen-Hoffmann said, in an interview with the Wisconsin State Journal."/>
BRIEF: Stratatech acquisition becomes final; jobs will stay in Madison, CEO says [The Wisconsin State Journal]
Opko Health, Inc. has closed its acquisition of Canada-based clinical stage biotechnology company Transition Therapeutics Inc., the company said on Wednesday. Under the terms of the agreement approved by the boards of directors of both companies, Transition Therapeutics security holders will receive approximately 6.4 m shares of Opko common stock. Based on the moving average price of Opko common stock for the five trading days..."/>
Opko Health Closes USD 60m Acquisition of Biotechnology Firm Transition Therapeutics
Community Health Options, the Maine-based health insurance cooperative, continued its financial recovery in the second quarter from a staggering $31 million loss in 2015.. The insurer reported on Wednesday a net loss of $3.3 million in the second quarter, down from a loss of $8.4 million in the first quarter. As of June 30, Community Health had $45.6 million remaining in reserves from premiums, borrowing, investments and other sources."/>
Community Health Options continues to recover from $31 million loss in 2015 [Portland Press Herald, Maine]
PAREXEL International Corporation concerning possible violations of federal securities laws. If you purchased or otherwise acquired PAREXEL shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you."/>
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against PAREXEL International Corporation and Advises Investors With Losses to Contact the Firm
American Renal Associates Holdings, Inc.. Investors who purchased or otherwise acquired shares 1) pursuant and/or traceable to the Initial Public Offering (“ IPO”) on or about April 21, 2016; and/or 2) on the open market between April 21, 2016 and August 18, 2016 (the“ Class Period”), are encouraged to contact the Firm in advance of the October 31, 2016 lead plaintiff motion deadline.."/>
INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against American Renal Associates Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
Coherus BioSciences, Inc., today announced that effective August 31, 2016, the compensation committee of the company’ s board of directors granted 6 new employees options to purchase an aggregate of 80,000 shares of the company’ s common stock with a per share exercise price of $29.77, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan,..."/>
Coherus BioSciences Announces New Employment Inducement Grants
Cynapsus Therapeutics Inc. today announced that the companies have signed a definitive agreement under which Sunovion will acquire Cynapsus for US $40.50 per share..."/>
Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
Invacare Corporation today announced its conference schedule for September 2016.. On Tuesday, September 13, at 12:30 p.m., Matthew E. Monaghan, Chairman, President and Chief Executive Officer, will present at CL King’ s 14th Annual Best Ideas Conference at the Omni Berkshire Place Hotel in New York. The live webcast of the presentation will be available at http://wsw.com/webcast/clk14/ivc, and it will be accessible for replay for 90 days following the conference."/>
Invacare Corporation to Present at September 2016 Conferences
Mallinckrodt plc, a leading specialty pharmaceutical company, today announced it closed the acquisition of Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft ® regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Under Mallinckrodt's..."/>
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
iKang Healthcare Group, Inc., the largest provider in China’ s fast growing private preventive healthcare services market with a market share of 13.6% in terms of revenue in calendar year 2014, today announced its unaudited financial results for the first quarter ended June 30, 2016.. Fiscal First Quarter Ended June 30, 2016 Financial Highlights. Net revenues were US $101.2 million, an increase of 17.3% year-over-year Gross profit was US $44.7 million, an..."/>
IKang Announces Unaudited Financial Results for the First Quarter Ended June 30, 2016
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the status of the Company’ s necuparanib program, at the 2016 Wells Fargo Healthcare Conference in Boston, MA. The presentation is scheduled to begin on Wednesday, September 7 th at 1:45 p.m. ET.. The audio webcast of the presentation will be..."/>
Momenta Pharmaceuticals to Webcast Presentation at the 2016 Wells Fargo Healthcare Conference
Quorum Health Corporation today announced that management will participate in the following conferences in September 2016:. September 7, 2016, at 8:45 a.m. at the Wells Fargo 2016 Healthcare Conference held at The Westin Boston Waterfront, Boston, MA. September 8, 2016, at 11:25 a.m. at the Baird 2016 Healthcare Conference held at The New York Palace, New York, NY."/>
Quorum Health Corporation to Participate in Two September Healthcare Conferences
BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that John V. Oyler, Founder, Chief Executive Officer, and Chairman, and Howard Liang, Ph.D., Chief Financial Officer and Chief Strategy Officer, will present at the following two upcoming investor conferences in New York City, NY:. Baird 2016 Global Healthcare Conference..."/>
BeiGene to Participate in Baird and Morgan Stanley Global Healthcare Conferences
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Wells Fargo Healthcare Conference in Boston on Weds., Sept. 7 at 4:05 p.m. ET/1: 05 p.m. PT. and at the Baird Global Healthcare Conference in New York on Thurs., Sept. 8 at 1:25 p.m. ET/10: 25 a.m. Helen Torley, president and CEO, will represent the company at both conferences."/>
Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
FEI Co. have voted in favour of the company's agreed deal to be acquired by US-based life science company Thermo Fisher Scientific Inc. for USD 107.50 per share in cash, the company said. The transaction, which was announced in May, represents a purchase price of approximately USD 4.2 bn. It is expected to be completed by the end of 2016.."/>
Electron Microscopy Firm FEI Wins Shareholder Nod for USD 4.2bn Thermo Fisher Buyout
OncoMed Pharmaceuticals, Inc. a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will provide a corporate update at two upcoming investor conferences.. 2016 Wells Fargo Healthcare Conference OncoMed’ s corporate presentation is scheduled for 2:55 pm ET on..."/>
OncoMed Management to Present at Two Upcoming Investment Conferences
Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that its president and chief executive officer, Ted W. Love, M.D. will participate in two upcoming investor conferences. Following are details for each presentation:. Wells Fargo Securities Healthcare Conference."/>
Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in September

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary532 Articles
Information Technology532 Articles
Financials412 Articles
Industrials328 Articles
Health Care318 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.